CAJ | 학술논문

目的：研究强化阿托伐他汀钙（立普托）治疗冠心病 CTO 病变高龄患者的临床疗效、安全性。方法将180例冠心病CTO病变高龄患者分为三组，各60例，对照组常规给予他汀药物及支架植入治疗，常规组给予20mg每日阿托伐他汀钙及支架植入治疗，强化组给予阿托伐他汀钙40mg每日强化治疗并且不植入支架，每组患者均使用双联抗血小板聚集，观察三组患者临床疗效、安全性的比较情况。结果随访5年，强化组患者临床有效率（85.00%）比对照组（63.33%）、常规组（68.33%）明显提高，而心血管危险事件发生率（21.67%）比其它两组（50.00%，38.33%）明显下降，比较有统计学意义（P＜0.05），且无明显不良反应。结论强化阿托伐他汀钙（立普妥）治疗高龄患者冠心病CTO病变可以明显提高患者临床有效率以及降低患者心血管危险事件发生，可以提高患者的生存质量。
목적：연구강화아탁벌타정개（립보탁）치료관심병 CTO 병변고령환자적림상료효、안전성。방법장180례관심병CTO병변고령환자분위삼조，각60례，대조조상규급여타정약물급지가식입치료，상규조급여20mg매일아탁벌타정개급지가식입치료，강화조급여아탁벌타정개40mg매일강화치료병차불식입지가，매조환자균사용쌍련항혈소판취집，관찰삼조환자림상료효、안전성적비교정황。결과수방5년，강화조환자림상유효솔（85.00%）비대조조（63.33%）、상규조（68.33%）명현제고，이심혈관위험사건발생솔（21.67%）비기타량조（50.00%，38.33%）명현하강，비교유통계학의의（P＜0.05），차무명현불량반응。결론강화아탁벌타정개（립보타）치료고령환자관심병CTO병변가이명현제고환자림상유효솔이급강저환자심혈관위험사건발생，가이제고환자적생존질량。
Objective Study on intensive atorvastatin calcium (vertical Puto) clinical efficacy in elderly patients with coronary heart disease, treatment of CTO lesions in safety.Methods 180 cases in elderly CTO patients were divided into three groups, al 60 cases, the control group were given conventional other Ting drug and stent implantation, the routine group were given 20mg daily atorvastatin calcium and stent implantation, strengthen the group were given atorvastatin 40mg daily intensive and no stent implantation, patients aggregation, to observe the three groups of patients with clinical curative effect, safety. Results 5 years of folow-up, patients in strengthen the group had clinical efficiency (85.00%) than in the control group (63.33%), control group (68.33%) was obviously improved, and the risk of cardiovascular events incidence rate (21.67%) than in the other two groups (50.00%, 38.33%) were significantly decreased, with a significant difference (P<0.05), and no significant adverse reaction.Conclusion Intensive atorvastatin(Lipitor)patients can significantly improve the clinical efficiency and reduce cardiovascular risk in patients with coronary heart disease events in treatment of CTO lesions in elderly patients, can survive for patients with elevated.